SG11202111678WA - Crystalline form of sofpironium bromide and preparation method thereof - Google Patents

Crystalline form of sofpironium bromide and preparation method thereof

Info

Publication number
SG11202111678WA
SG11202111678WA SG11202111678WA SG11202111678WA SG11202111678WA SG 11202111678W A SG11202111678W A SG 11202111678WA SG 11202111678W A SG11202111678W A SG 11202111678WA SG 11202111678W A SG11202111678W A SG 11202111678WA SG 11202111678W A SG11202111678W A SG 11202111678WA
Authority
SG
Singapore
Prior art keywords
preparation
crystalline form
sofpironium bromide
sofpironium
bromide
Prior art date
Application number
SG11202111678WA
Other languages
English (en)
Inventor
Kazuyoshi MARUBAYASHI
Masahito Watanabe
Herbert R Brinkman
Original Assignee
Kaken Pharma Co Ltd
Brickell Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharma Co Ltd, Brickell Biotech Inc filed Critical Kaken Pharma Co Ltd
Publication of SG11202111678WA publication Critical patent/SG11202111678WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/147Saturated compounds having only one carboxyl group and containing —CHO groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11202111678WA 2019-05-23 2020-05-22 Crystalline form of sofpironium bromide and preparation method thereof SG11202111678WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962851880P 2019-05-23 2019-05-23
PCT/JP2020/020210 WO2020235665A1 (en) 2019-05-23 2020-05-22 Crystalline form of sofpironium bromide and preparation method thereof

Publications (1)

Publication Number Publication Date
SG11202111678WA true SG11202111678WA (en) 2021-11-29

Family

ID=72146250

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111678WA SG11202111678WA (en) 2019-05-23 2020-05-22 Crystalline form of sofpironium bromide and preparation method thereof

Country Status (16)

Country Link
US (3) US20220298108A1 (zh)
EP (1) EP3972955A4 (zh)
JP (2) JP6748329B1 (zh)
KR (1) KR20220011671A (zh)
CN (1) CN114008023B (zh)
AU (1) AU2020277881A1 (zh)
BR (1) BR112021023241A2 (zh)
CA (1) CA3139948A1 (zh)
CL (1) CL2021003047A1 (zh)
CO (1) CO2021017456A2 (zh)
IL (1) IL288285A (zh)
MX (1) MX2021014163A (zh)
SG (1) SG11202111678WA (zh)
TW (2) TWI838531B (zh)
WO (1) WO2020235665A1 (zh)
ZA (1) ZA202109514B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4002383A3 (en) 2020-11-13 2022-08-03 Tokyo Institute of Technology Information processing device, information processing method, recording medium recording information processing program, and information processing system

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
JP5257073B2 (ja) * 2005-11-10 2013-08-07 ボーダー、ニコラス・エス ソフト型抗コリン作動性エステル
US7399861B2 (en) * 2005-11-10 2008-07-15 Bodor Nicholas S Soft anticholinergic esters
MX357741B (es) * 2012-07-06 2018-07-23 Laboratorios Senosiain S A De C V Star Nuevas formas sólidas de inhibidores de fosfodiesterasa tipo 5.
US9512166B2 (en) * 2012-09-05 2016-12-06 Amri Ssci, Llc Cocrystals of progesterone
US20150259283A1 (en) * 2014-03-13 2015-09-17 Brickell Biotech, Inc. Formulation for soft anticholinergic analogs
US10906871B2 (en) * 2016-08-02 2021-02-02 Dermira, Inc. Processes for making, and methods of using, glycopyrronium compounds

Also Published As

Publication number Publication date
WO2020235665A1 (en) 2020-11-26
CA3139948A1 (en) 2020-11-26
US20210395197A1 (en) 2021-12-23
US11566000B2 (en) 2023-01-31
TW202411205A (zh) 2024-03-16
JP2020189856A (ja) 2020-11-26
IL288285A (en) 2022-01-01
CL2021003047A1 (es) 2022-09-20
EP3972955A4 (en) 2023-07-05
ZA202109514B (en) 2023-12-20
JP2020189839A (ja) 2020-11-26
AU2020277881A1 (en) 2021-12-09
TWI838531B (zh) 2024-04-11
CN114008023A (zh) 2022-02-01
MX2021014163A (es) 2022-01-04
CO2021017456A2 (es) 2022-01-17
US20220298108A1 (en) 2022-09-22
JP6748329B1 (ja) 2020-08-26
US20210171460A1 (en) 2021-06-10
TW202110796A (zh) 2021-03-16
EP3972955A1 (en) 2022-03-30
BR112021023241A2 (pt) 2022-01-04
KR20220011671A (ko) 2022-01-28
CN114008023B (zh) 2024-02-09
US11584715B2 (en) 2023-02-21

Similar Documents

Publication Publication Date Title
EP3502113A4 (en) PHARMACEUTICALLY ACCEPTABLE SALT OF EGFR INHIBITOR, CRYSTALLINE FORM THEREOF, PREPARATION METHOD AND APPLICATION THEREOF
EP3677575A4 (en) CRYSTALLINE FORM OF OZANIMODHYDROCHLORIDE AND PRODUCTION METHOD THEREFOR
EP3842426A4 (en) PREPARATION PROCESS OF PYRROLO-AMINO-PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF
EP3530650A4 (en) CRYSTALLINE FORM OF (R) -4-HYDROXY-2-OXO-1-PYRROLIDINE ACETAMIDE, PRODUCTION METHOD THEREFOR, AND USE THEREOF
IL289231A (en) Salts of compounds, their crystalline forms and their uses
IL272108A (en) New crystal structures of vilanterol tripentate and processes for their preparation
PT3766884T (pt) Forma cristalina e tipo de sal de composto de triazolopirimidina e método de preparação associado
EP3327012A4 (en) Crystalline forms of bilastine and preparation methods thereof
EP3658278A4 (en) CRYSTALLINE METALLOPHOSPHATES, THEIR PREPARATION PROCESS AND THEIR USE
IL289453A (en) A process for the preparation of ridinilazole and crystalline forms thereof
EP3725786A4 (en) CRYSTAL SHAPE AND SALT SHAPE OF A TGF-BRI INHIBITOR AND METHOD OF MANUFACTURING IT
ZA202106233B (en) Method of improving sleep
IL288285A (en) Crystalline form of sophironium bromide and method of preparation
PL4061772T3 (pl) Sposób wytwarzania argyrodytu litowego
EP3744712A4 (en) CRYSTALLINE FORMS OF MESACONIN AND THE MANUFACTURING PROCESS FOR IT
GB201918401D0 (en) Novel crystalline forms of Flufenacet, methods for their preparation and use of the same
EP3985009C0 (en) B-CRYSTAL FORM OF A TETRAHYDROTHIENOPYRIDINE COMPOUND, METHOD FOR ITS PREPARATION, COMPOSITION AND APPLICATION
EP3366676A4 (en) CRYSTALLINE FORMS OF BEDAQUILINE FUMARATE AND MANUFACTURING METHOD THEREFOR
PL3692127T3 (pl) Substancje pro-zapachowe i sposób ich wytwarzania
IL254597A0 (en) Crystalline form of ahu377, method for its preparation and use
EP3348546A4 (en) CRYSTALLINE FORM OF ANDROGEN RECEPTOR INHIBITOR AND PREPARATION METHOD THEREOF
GB201918391D0 (en) Novel crystalline forms of flufenacet, methods for their preparation and use of the same
EP3793546A4 (en) CRYSTALLINE FORMS OF EBNA1-INHIBITOR AND METHOD OF MANUFACTURING AND USING THEREOF
PL3692126T3 (pl) Substancje pro-zapachowe i sposób ich wytwarzania
EP3658504A4 (en) CRYSTALLINE METALLOPHOSPHATES, THEIR PREPARATION PROCESS AND THEIR USE